Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: Recommendations for JC virus serology;Risikostratifizierung einer progressiven multifokalen Leukenzephalopathie unter Natalizumab: Empfehlungen zur JC-Virus-Serologie

Nervenarzt

Volumn 82, Issue 10, 2011, Pages 1314-1319

  Warnke, C ^a   Adams, O ^a   Hartung, H P ^a   Gold, R ^b   Hemmer, B ^c   Hohlfeld, R ^d   Stangel, M ^e   Zipp, F ^f   Wiendl, H ^g   Kieseier, B C ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Antibody; JC virus; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

NATALIZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ARTICLE; HUMAN; JC VIRUS; MULTIPLE SCLEROSIS; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; SEROLOGY; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; IMMUNOLOGY; LONG TERM CARE; NOTE; RISK FACTOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LONG-TERM CARE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK FACTORS;

EID: 80755130444     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-011-3319-2     Document Type: Article

References (22)

1. Warnke C, Adams O, Gold R et al (2011) Progressive multifokale Leukoenzephalopathie unter Natalizumab: Erste Möglichkeiten einer Risikostratifizierung? Nervenarzt (Epub ahead of print)
2. Gorelik L, Lerner M, Bixler S et al (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295-303
3. West TW, Cree BA (2010) Natalizumab dosage suspension: are we helping or hurting? Ann Neurol 68:395-399.
4. Kaufman MD, Lee R, Norton H (2011) Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler 17(4):490-494
5. Sandrock A, Hotermans C, Richman S et al (2011) Risk Stratification for progressive multifocal leukoencephalopathy (PML) in MS patients: role of prior immunosuppressant use, natalizumab-treatment duration, and anti-JCV antibody status. Neurology 76(Suppl 4) P03.248
6. Verbeeck J, Van Assche G, Ryding J et al (2008) JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 57:1393-1397
7. Stolt A, Sasnauskas K, Koskela P et al (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84:1499-1504 (Pubitemid 36675520)
8. Kean JM, Rao S, Wang M, Garcea RL (2009) Seroepidemiology of human polyomaviruses. PLoS Pathog 5:e1000363
9. Egli A, Infanti L, Dumoulin A et al (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837-846
10. Knowles WA, Pipkin P, Andrews N, et al (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115-123 (Pubitemid 37121921)
11. Matos A, Duque V, Beato S et al (2010) Characterization of JC human polyomavirus infection in a Portuguese population. J Med Virol 82:494-504
12. Goelz SE, Gorelik L, Subramanyam M (2010) Assay design and sample collection can affect anti-John Cunningham virus antibody detection. Ann Neurol 68(3):304-310
13. Cohen JA, Barkhof F, Comi G et al (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415
14. Kappos L, Radue EW, O'Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401
15. Aktas O, Ingwersen J, Kieseier BC et al (2011) Orales Fingolimod bei Multipler Sklerose. Therapeutische Modulation des Sphingosin-1-Phosphat-Systems. Nervenarzt 82:215-225
16. www.whocc.no/atc-ddd-index/?code=L04AA
17. Mehling M, Johnson TA, Antel J et al (2011) Clinical immunology of the sphingosine 1-phsophate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology 76(Suppl 3):20-27
18. Kowarik MC, Pellkofer HL, Cepok S et al (2011) Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology 76:1214-1221
19. Tan CS, Koralnik IJ (2010) Progressive multifocal leukoencephalopathy and other disorders caused by JC virus- clinical features and pathogenesis. Lancet Neurol 9:425-437
20. Warnke C, Menge T, Hartung HP et al (2010) Natalizumab and progressive multifocal leukoencephalopathy what are the causal factors and can it be avoided? Arch Neurol 67:923-930
21. Haghikia A, Perrech M, Pula B et al (2011) Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PLoS One (in press)
22. O'Connor PW, Goodman A, Kappos L et al (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (Epub ahead of print)